{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T18:14:50Z","timestamp":1776708890997,"version":"3.51.2"},"reference-count":37,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T00:00:00Z","timestamp":1686441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jiph.2023.06.009","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T20:44:08Z","timestamp":1686861848000},"page":"1485-1491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Outcome of patients with carbapenem-resistant Acinetobacter baumannii infections treated with cefiderocol: A multicenter observational study"],"prefix":"10.1016","volume":"16","author":[{"given":"Federica","family":"Cal\u00f2","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Onorato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margherita","family":"Macera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2622-0573","authenticated-orcid":false,"given":"Caterina","family":"Monari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Durante-Mangoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Massa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Di Caprio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Pagliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio Giuliano","family":"Numis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Iuliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Riccardo","family":"Buonomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastiano","family":"Leone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8772-0136","authenticated-orcid":false,"given":"Paolo","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5897-4949","authenticated-orcid":false,"given":"Nicola","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiph.2023.06.009_bib1","unstructured":"Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022 Feb 12;399(10325):629\u2013655. doi: 10.1016\/S0140\u20136736(21)02724\u20130. Epub 2022 Jan 19. Erratum in: Lancet. 2022 Oct 1;400(10358):1102. PMID: 35065702; PMCID: PMC8841637."},{"key":"10.1016\/j.jiph.2023.06.009_bib2","unstructured":"World Health Organization. 2021. WHO publishes list of bacteria for which new antibiotics are urgently needed. https:\/\/www.who.int\/news\/item\/27\u201302-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed."},{"key":"10.1016\/j.jiph.2023.06.009_bib3","unstructured":"European Centre for Disease Prevention and Control; Antimicrobial Resistance Surveillance in Europe 2022\u20132020 Data. [(accessed on 1 November 2022)]. Available online: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/antimicrobial-resistance-surveillance-europe-2022\u20132020-data."},{"key":"10.1016\/j.jiph.2023.06.009_bib4","unstructured":"Trama U., Signoriello G., D\u2019Agostino F., Sarnelli B.Rapporto 2019 sull\u2019antibiotico resistenza e sull\u2019uso di antibiotici rilevati nelle strutture pubbliche del sistema sanitario della Campania. Assessorato alla Sanit\u00e0 della Regione Campania, Direzione Generale per la Tutela della Salute ed il Coordinamento del Sistema Sanitario Regionale [(accessed on 1 November 2022)]. Available online: http:\/\/www.regione.campania.it\/regione\/it\/tematiche\/antibiotico-resistenza-ed-infezioni-correlate-all-assistenza-64in."},{"key":"10.1016\/j.jiph.2023.06.009_bib5","doi-asserted-by":"crossref","unstructured":"Pogue J.M., Zhou Y., Kanakamedala H., Cai B. Burden of illness in carbapenem-resistant Acinetobacter baumannii infections in US hospitals between 2014 and 2019. BMC Infect Dis. 2022 Jan 6;22(1):36.","DOI":"10.1186\/s12879-021-07024-4"},{"issue":"9","key":"10.1016\/j.jiph.2023.06.009_bib6","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3390\/antibiotics11091263","article-title":"Epidemiology, mechanisms of resistance and treatment algorithm for infections due to carbapenem-resistant gram-negative bacteria: an expert panel opinion","volume":"11","author":"Coppola","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.jiph.2023.06.009_bib7","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.cmi.2018.01.015","volume":"24","author":"Papst","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiph.2023.06.009_bib8","unstructured":"Tamma P.D., Aitken S.L., Bonomo R.A., Mathers A.J., van Duin D., Clancy C.J. Infectious Diseases Society of America Guidance on the Treatment of AmpC \u03b2-lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections. Infectious Diseases Society of America 2022; Version 2.0. Available at https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance-2.0\/. Accessed 04\/05\/2023."},{"issue":"4","key":"10.1016\/j.jiph.2023.06.009_bib9","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiph.2023.06.009_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlaa060","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe","author":"Longshaw","year":"2020","journal-title":"JAC Antimicrob Resist"},{"issue":"2","key":"10.1016\/j.jiph.2023.06.009_bib11","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.jiph.2023.06.009_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"373\u201383","key":"10.1016\/j.jiph.2023.06.009_bib13","first-page":"12","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.jiph.2023.06.009_bib14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/1757177415617245","article-title":"The reliability of the McCabe score as a marker of co-morbidity in healthcare-associated infection point prevalence studies","volume":"17","author":"Reilly","year":"2016","journal-title":"J Infect Prev"},{"key":"10.1016\/j.jiph.2023.06.009_bib15","unstructured":"CDC, 2021. CDC\/NHSN Surveillance Definitions for Specific Types of Infections. Available online: https:\/\/www.cdc.gov\/nhsn\/pdfs\/pscmanual\/17pscnosinfdef_current.pdf."},{"key":"10.1016\/j.jiph.2023.06.009_bib16","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"J Am Med Assoc"},{"issue":"5","key":"10.1016\/j.jiph.2023.06.009_bib17","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1097\/CCM.0b013e31819def97","article-title":"The sequential organ failure assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation","volume":"37","author":"Jones","year":"2009","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jiph.2023.06.009_bib18","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0002-9343(89)80611-4","article-title":"Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients","volume":"87","author":"Hilf","year":"1989","journal-title":"Am J Med"},{"issue":"5 Pt 1","key":"10.1016\/j.jiph.2023.06.009_bib19","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1164\/ajrccm\/143.5_Pt_1.1121","article-title":"Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic \"blind\" bronchoalveolar lavage fluid","volume":"143","author":"Pugin","year":"1991","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jiph.2023.06.009_bib20","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jgar.2021.02.004","article-title":"Clinical efficacy and safety of cefiderocol in the treatment of acute bacterial infections: a systematic review and meta-analysis of randomised controlled trials","volume":"24","author":"Hsueh","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jiph.2023.06.009_bib21","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiph.2023.06.009_bib22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, Phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiph.2023.06.009_bib23","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jgar.2020.09.019","article-title":"Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii","volume":"23","author":"Oliva","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"issue":"11","key":"10.1016\/j.jiph.2023.06.009_bib24","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1093\/cid\/ciaa1410","article-title":"Cefiderocol as rescue therapy for acinetobacter baumannii and other carbapenem-resistant gram-negative infections in intensive care unit patients","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jiph.2023.06.009_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106723","article-title":"Clinical efficacy and safety of cefiderocol for resistant Gram-negative infections: a real-life, single-centre experience","volume":"Feb;61","author":"Karruli","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiph.2023.06.009_bib26","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.jiph.2023.06.009_bib27","doi-asserted-by":"crossref","first-page":"dlab174","DOI":"10.1093\/jacamr\/dlab174","article-title":"Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study","volume":"3","author":"Pascale","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.jiph.2023.06.009_bib28","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cid\/cit253","article-title":"Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial","volume":"57","author":"Durante-Mangoni","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2023.06.009_bib29","first-page":"8","article-title":"Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection","volume":"5","author":"Chen","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jiph.2023.06.009_bib30","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1128\/AAC.02435-13","article-title":"Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumanniiinfections","volume":"58","author":"Sirijatuphat","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.jiph.2023.06.009_bib31","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/14787210.2022.2020099","article-title":"All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies","volume":"20","author":"Lodise","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"10.1016\/j.jiph.2023.06.009_bib32","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200131","article-title":"Colistin monotherapy versus combination therapy for carbapenem-resistant organisms","volume":"2","author":"Kaye","year":"2023","journal-title":"NEJM Evid"},{"issue":"3","key":"10.1016\/j.jiph.2023.06.009_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01975-21","article-title":"Treatment, clinical outcomes, and predictors of mortality among a national cohort of admitted patients with acinetobacter baumannii infection","volume":"66","author":"Appaneal","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.jiph.2023.06.009_bib34","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.ajic.2019.03.003","article-title":"Predictors of mortality in patients infected with carbapenem-resistant acinetobacter baumannii: a systematic review and meta-analysis","volume":"47","author":"Du","year":"2019","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.jiph.2023.06.009_bib35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jgar.2022.08.010","article-title":"Korea Infectious Diseases (KIND) Study Group.Risk factors for early mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteraemia","volume":"31","author":"Lee","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"issue":"2","key":"10.1016\/j.jiph.2023.06.009_bib36","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jinf.2019.05.017","article-title":"ISGRI-SITA (Italian Study Group on Resistant Infections of the Societ\u00e0 Italiana Terapia Antinfettiva). bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study","volume":"79","author":"Russo","year":"2019","journal-title":"J Infect"},{"issue":"4","key":"10.1016\/j.jiph.2023.06.009_bib37","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/jac\/dkad032","article-title":"In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime\/avibactam, ampicillin\/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii","volume":"78","author":"Gill","year":"2023","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034123002150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034123002150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:24:07Z","timestamp":1761751447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034123002150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1876034123002150"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2023.06.009","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2680614\/v1","asserted-by":"object"}]},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome of patients with carbapenem-resistant Acinetobacter baumannii infections treated with cefiderocol: A multicenter observational study","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2023.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}]}}